MXPA05011755A - Composiciones y metodos para inmunoterapia especifica de tumor wilms 1. - Google Patents

Composiciones y metodos para inmunoterapia especifica de tumor wilms 1.

Info

Publication number
MXPA05011755A
MXPA05011755A MXPA05011755A MXPA05011755A MXPA05011755A MX PA05011755 A MXPA05011755 A MX PA05011755A MX PA05011755 A MXPA05011755 A MX PA05011755A MX PA05011755 A MXPA05011755 A MX PA05011755A MX PA05011755 A MXPA05011755 A MX PA05011755A
Authority
MX
Mexico
Prior art keywords
compositions
polypeptide
methods
specific immunotherapy
presenting
Prior art date
Application number
MXPA05011755A
Other languages
English (en)
Inventor
Nomalie Jaya
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Publication of MXPA05011755A publication Critical patent/MXPA05011755A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen composiciones y metodos para la terapia de enfermedades malignas, tales como leucemia y cancer; las composiciones comprenden uno o mas polinucleotidos de WT1, un polipeptido de WT1, una celula que presenta antigenos que presenta un polipeptido de WT1, un anticuerpo que se une especificamente a un polipeptido de WT1; o una celula T que reacciona especificamente con un polipeptido de WT1; dichas composiciones pueden utilizarse, por ejemplo, para la prevencion o tratamiento de enfermedades metastasicas.
MXPA05011755A 2003-04-30 2004-04-29 Composiciones y metodos para inmunoterapia especifica de tumor wilms 1. MXPA05011755A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/427,717 US7553494B2 (en) 2001-08-24 2003-04-30 WT1 fusion proteins
PCT/US2004/013240 WO2004100870A2 (en) 2003-04-30 2004-04-29 Compositions and methods for wt1 specific immunotherapy

Publications (1)

Publication Number Publication Date
MXPA05011755A true MXPA05011755A (es) 2006-02-17

Family

ID=33449619

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05011755A MXPA05011755A (es) 2003-04-30 2004-04-29 Composiciones y metodos para inmunoterapia especifica de tumor wilms 1.

Country Status (16)

Country Link
US (2) US7553494B2 (es)
EP (1) EP1617863A4 (es)
JP (1) JP2007515393A (es)
KR (1) KR20060054176A (es)
CN (1) CN1816349A (es)
AU (1) AU2004238226A1 (es)
BR (1) BRPI0409879A (es)
CA (1) CA2523943A1 (es)
CO (1) CO5700788A2 (es)
MA (1) MA27873A1 (es)
MX (1) MXPA05011755A (es)
NO (1) NO20055347L (es)
RU (1) RU2005137167A (es)
TW (1) TW200509967A (es)
WO (1) WO2004100870A2 (es)
ZA (1) ZA200509609B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI9912663B8 (pt) * 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US7329410B1 (en) * 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7901693B2 (en) * 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CN1281625C (zh) * 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
WO2005087260A1 (en) * 2004-03-04 2005-09-22 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
CA2900087C (en) 2005-10-17 2024-02-13 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP3117836A1 (en) * 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
TWI426269B (zh) * 2006-08-14 2014-02-11 Academia Sinica 胃液蛋白分析於胃癌鑑定之方法
PT2341142E (pt) 2006-12-28 2015-02-13 Int Inst Cancer Immunology Inc Péptido wt1 restringido a hla-a*1101 e composição farmacêutica compreendendo o mesmo
AU2012227350C1 (en) * 2006-12-28 2015-11-12 International Institute Of Cancer Immunology, Inc. HLA-A*1101-Restricted WT1 peptide and pharmaceutical composition comprising the same
SI2119778T1 (sl) * 2007-02-27 2016-03-31 International Institute Of Cancer Immunology, Inc. Postopek aktivacije celice T pomagalke in sestavek za uporabo postopka
KR101238795B1 (ko) * 2007-05-24 2013-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
AR076284A1 (es) * 2009-04-29 2011-06-01 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
NZ743310A (en) * 2011-03-23 2022-11-25 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
US9074000B2 (en) * 2011-04-01 2015-07-07 Memorial Sloan Kettering Cancer Center T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2014031178A1 (en) * 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
MX364732B (es) * 2012-12-13 2019-05-06 Univ Pennsylvania Vacuna contra el tumor de wilms 1.
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
RS61173B1 (sr) 2013-01-15 2021-01-29 Memorial Sloan Kettering Cancer Center Imunogeni wt-1 peptidi i postupci za njihovu upotrebu
EP2762156A1 (en) * 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
JP6497691B2 (ja) * 2013-02-05 2019-04-10 日東電工株式会社 粘膜投与用ｗｔ１ペプチド癌ワクチン組成物
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
KR101804343B1 (ko) * 2014-02-26 2017-12-04 텔라 가부시키가이샤 Ｗｔ１ 항원성 폴리펩티드 및 상기 폴리펩티드를 포함하는 항종양제
US10739344B2 (en) * 2014-12-29 2020-08-11 West Virginia University Zinc finger linker (ZnFL) antibody
CN108350411B (zh) * 2015-06-25 2021-06-22 白川利朗 口服肿瘤疫苗
MD3377516T2 (ro) 2015-11-20 2022-10-31 Memorial Sloan Kettering Cancer Center Metode și compoziții pentru tratarea cancerului
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
CN105713874A (zh) * 2016-01-29 2016-06-29 深圳市中美康士生物科技有限公司 一种抗肿瘤相关抗原wt1特异性ctl及其制备方法
EP3549957A4 (en) 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. WT1-HELPER PEPTIDE AND COMBINATION OF THE SAYING PEPTIDE AND A CANCER ANTIGEN PEPTIDE CONJUGATE
JPWO2018181648A1 (ja) 2017-03-30 2020-02-13 大日本住友製薬株式会社 Ｗｔ１癌抗原ペプチドおよびこれを含むペプチドコンジュゲート体
WO2020067453A1 (ja) 2018-09-28 2020-04-02 大日本住友製薬株式会社 注射用組成物
KR20230009426A (ko) * 2020-05-12 2023-01-17 스미토모 파마 가부시키가이샤 암을 처치하기 위한 의약 조성물
KR20240046880A (ko) 2021-08-12 2024-04-11 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암을 처치 또는 예방하기 위한 의약 조성물 및 방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69033127T2 (de) * 1989-11-13 1999-10-14 Massachusetts Inst Technology Lokalisation und charakterisierung des wilms-tumor-gens
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
DE69219787T2 (de) * 1991-11-29 1997-08-28 Viagene Inc Immuntherapeutische vektorkonstrukte gegen krebs
JPH07504683A (ja) * 1992-07-08 1995-05-25 シェリング・コーポレーション Ｇｍ−ｃｓｆのワクチンアジュバントとしての利用
JP2735986B2 (ja) 1992-10-16 1998-04-02 株式会社セラリカ野田 癌抑制遺伝子ｗｔの産物に対する抗体
WO1994021287A1 (en) 1993-03-15 1994-09-29 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Peptide coated dendritic cells as immunogens
US5705159A (en) 1993-08-31 1998-01-06 John Wayne Cancer Institute Immunoreactive peptide sequence from a 43 KD human cancer antigen
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5670317A (en) 1995-05-08 1997-09-23 Sloan-Kettering Institute For Cancer Research Diagnostic test for the desmoplastic small round cell tumor
EP0841068B1 (en) 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6818751B1 (en) * 1997-08-01 2004-11-16 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
JP4789095B2 (ja) 1997-07-16 2011-10-05 治夫 杉山 ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤
JPH1189596A (ja) 1997-09-19 1999-04-06 Takara Shuzo Co Ltd Ｒｎａ量の測定方法並びに測定キット
JPH1189599A (ja) 1997-09-24 1999-04-06 Haruo Sugiyama 補正競合ｒｔ−ｐｃｒ法によるヒトｗｔ１発現定量法
EP1068339B1 (en) 1998-04-01 2008-07-23 The Governors of the University of Alberta Compositions and methods for protein secretion
WO1999058135A1 (en) 1998-05-11 1999-11-18 The Salk Institute For Biological Studies Compositions for the treatment of tumors, and uses thereof
BRPI9912663B8 (pt) 1998-07-31 2021-07-06 Int Inst Cancer Immunology Inc vacina contra cáncer e polipeptìdeo.
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
IL142216A0 (en) 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US20030072767A1 (en) * 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) * 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) * 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
AU7859900A (en) 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
CA2401070A1 (en) 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
CN1314359A (zh) 2000-03-17 2001-09-26 上海博德基因开发有限公司 一种新的多肽——肿瘤抑制因子63和编码这种多肽的多核苷酸
EP1358349A2 (en) 2000-06-05 2003-11-05 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
ATE312932T1 (de) * 2000-09-18 2005-12-15 Genencor Int Zwillingsarginin translokation in bacillus
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins

Also Published As

Publication number Publication date
MA27873A1 (fr) 2006-05-02
WO2004100870A3 (en) 2005-03-31
NO20055347L (no) 2006-01-27
US7915393B2 (en) 2011-03-29
US20090312403A1 (en) 2009-12-17
ZA200509609B (en) 2007-04-25
CA2523943A1 (en) 2004-11-25
TW200509967A (en) 2005-03-16
NO20055347D0 (no) 2005-11-11
BRPI0409879A (pt) 2006-05-16
WO2004100870A2 (en) 2004-11-25
CN1816349A (zh) 2006-08-09
EP1617863A4 (en) 2007-12-19
RU2005137167A (ru) 2006-06-27
EP1617863A2 (en) 2006-01-25
CO5700788A2 (es) 2006-11-30
US20040018204A1 (en) 2004-01-29
JP2007515393A (ja) 2007-06-14
KR20060054176A (ko) 2006-05-22
US7553494B2 (en) 2009-06-30
AU2004238226A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
MXPA05011755A (es) Composiciones y metodos para inmunoterapia especifica de tumor wilms 1.
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
WO2003037060A3 (en) Compositions and methods for wt1 specific immunotherapy
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
IL258880A (en) Compounds of diarylhydantoin
IN2012DN01964A (es)
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
WO2004101762A3 (en) Detection and treatment of cancers of the colon
WO2003024302A3 (en) Detection and treatment of cancers of breast
WO2003024304A3 (en) Detection and treatment of cancers of the liver
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
WO2004069209A3 (en) Compositions and methods for increasing the sensitivity of apoptosis-resistant tumor cells to inducers of apoptosis
WO2024083925A3 (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
WO2003079977A3 (en) Novel compositions and methods in cancer associated with altered expression of mcm3ap